Kevin T. Chaung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin T. Chaung has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Mindie H. Nguyen
Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
12 shared publications - Huy N. Trinh
Pacific Health Foundation
10 shared publications - Huy A. Nguyen
San Jose Gastroenterology
8 shared publications - Khanh K. Nguyen
San Jose Gastroenterology
6 shared publications - Brian S. Levitt
San Jose Gastroenterology
5 shared publications - Nghiem B. Ha
Stanford University Medical Center
5 shared publications
Latest Publications
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1081-S1082
High Rate of Progression to Cirrhosis in Chronic Hepatitis B (CHB) Patients with Non-Alcoholic Fatty Liver (FL)
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1081-S1082
High Rate of Progression to Cirrhosis in Chronic Hepatitis B (CHB) Patients with Non-Alcoholic Fatty Liver (FL)
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1072
Metabolic Syndrome Increases the Incidence of Cirrhosis and Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1072
Metabolic Syndrome Increases the Incidence of Cirrhosis and Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
- 1 October 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (11) , 3342-3347
Less-Established Risk Factors Are Common in Asian Americans with Hepatitis C Virus: A Case–Controlled Study
- 1 October 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (11) , 3342-3347
Less-Established Risk Factors Are Common in Asian Americans with Hepatitis C Virus: A Case–Controlled Study
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Sa1006 Effectiveness of Oral Antiviral Therapy for Treatment-Naive Chronic Hepatitis B (CHB) in Routine Clinical Practice
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Sa1006 Effectiveness of Oral Antiviral Therapy for Treatment-Naive Chronic Hepatitis B (CHB) in Routine Clinical Practice
- 26 September 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (11) , 3011-3016
Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders
Despite high potency, a significant proportion of patients treated with entecavir achieve only partial viral suppression. Our goal was to examine the complete viral suppression rate (undetectable HBV DNA PCR levels) with alternative therapies in such patients. We retrospectively studied 42 consecutive patients with partial response to entecavir (detectable HBV DNA at ≥12 months of therapy) who were treated at three clinics with rescue therapies: entecavir + adefovir (n = 5), tenofovir (n = 6), and entecavir + tenofovir (n = 31). Antiviral resistance was excluded by negative mutation analysis and/or absence of virologic breakthrough (increase >1 log10IU/mL from nadir). All patients were Asian and 57 % were male with a median age of 36 (22–64) years. Only a few patients had prior exposure to lamivudine (7 %) or adefovir (7 %). Almost all patients (95 %) had positive HBeAg. Overall, the complete viral suppression rate was 79 %, and the alanine aminotransferase normalization rate was 83 % in entecavir partial responders after 6 months on rescue therapies. Cumulative complete viral suppression rates were significantly different (P = 0.0164) among the entecavir + adefovir, tenofovir, and entecavir + tenofovir treatment groups at 6 months (20 vs. 83 vs. 83 %, respectively) and 12 months (20 vs. 100 vs. 97 %). All three patients without complete viral suppression on entecavir + adefovir became aviremic 6 months after switching to entecavir + tenofovir. Virologic response to entecavir + tenofovir combination therapy and tenofovir monotherapy appeared to be similar in most patients, but not with the entecavir + adefovir combination.
- 26 September 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (11) , 3011-3016
Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders
Despite high potency, a significant proportion of patients treated with entecavir achieve only partial viral suppression. Our goal was to examine the complete viral suppression rate (undetectable HBV DNA PCR levels) with alternative therapies in such patients. We retrospectively studied 42 consecutive patients with partial response to entecavir (detectable HBV DNA at ≥12 months of therapy) who were treated at three clinics with rescue therapies: entecavir + adefovir (n = 5), tenofovir (n = 6), and entecavir + tenofovir (n = 31). Antiviral resistance was excluded by negative mutation analysis and/or absence of virologic breakthrough (increase >1 log10IU/mL from nadir). All patients were Asian and 57 % were male with a median age of 36 (22–64) years. Only a few patients had prior exposure to lamivudine (7 %) or adefovir (7 %). Almost all patients (95 %) had positive HBeAg. Overall, the complete viral suppression rate was 79 %, and the alanine aminotransferase normalization rate was 83 % in entecavir partial responders after 6 months on rescue therapies. Cumulative complete viral suppression rates were significantly different (P = 0.0164) among the entecavir + adefovir, tenofovir, and entecavir + tenofovir treatment groups at 6 months (20 vs. 83 vs. 83 %, respectively) and 12 months (20 vs. 100 vs. 97 %). All three patients without complete viral suppression on entecavir + adefovir became aviremic 6 months after switching to entecavir + tenofovir. Virologic response to entecavir + tenofovir combination therapy and tenofovir monotherapy appeared to be similar in most patients, but not with the entecavir + adefovir combination.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Mo1902 Hepatitis B Surface Antigen (HBsAg) Seroclearance Rate in a Multicenter U.S. Cohort Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Mo1902 Hepatitis B Surface Antigen (HBsAg) Seroclearance Rate in a Multicenter U.S. Cohort Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints